These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9398136)

  • 1. Cyclophosphamide therapy of severe lupus nephritis.
    Appel GB
    Am J Kidney Dis; 1997 Dec; 30(6):872-6; discussion 876-8. PubMed ID: 9398136
    [No Abstract]   [Full Text] [Related]  

  • 2. Bullous systemic lupus erythematosus induced by the therapy for lupus nephritis.
    Jedlickova H; Bohmová J; Sirotkova A
    Int J Dermatol; 2008 Dec; 47(12):1315-6. PubMed ID: 19126028
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network.
    Dooley MA; Hogan S; Jennette C; Falk R
    Kidney Int; 1997 Apr; 51(4):1188-95. PubMed ID: 9083285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High doses of cyclophosphamide in the treatment of severe systemic lupus erythematosus.
    Glisic B; Popovic M; Popovic R; Mitrovic D; Stefanovic D; Dimitrijevic M
    Transplant Proc; 2001 May; 33(3):2300-1. PubMed ID: 11377536
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.
    Boletis JN; Ioannidis JP; Boki KA; Moutsopoulos HM
    Lancet; 1999 Aug; 354(9178):569-70. PubMed ID: 10470708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Invasive disseminated aspergillosis in combined immunosuppressive therapy in systemic lupus erythematosus].
    Teuber G; Schwarting A; Mildenberger P; Schmidt-Brücken G; Moll R; Bornemann A; Wandel E; Wanitschke R; Meyer zum Büschenfelde KH
    Med Klin (Munich); 1996 Dec; 91(12):798-801. PubMed ID: 9082168
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cyclophosphamide therapy in systemic lupus erythematosus].
    Backhaus M; Hiepe F
    Z Rheumatol; 1997; 56(4):178-89. PubMed ID: 9417758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Illness perceptions in patients with systemic lupus erythematosus and proliferative lupus nephritis.
    Daleboudt GM; Broadbent E; Berger SP; Kaptein AA
    Lupus; 2011 Mar; 20(3):290-8. PubMed ID: 21362752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive treatment for proliferative lupus nephritis.
    Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-related myelodysplastic syndrome following cyclophosphamide pulse and/or methotrexate therapy in a patient with systemic lupus erythematosus.
    Iwadate H; Kobayashi H; Yano K; Watanabe H; Ikeda K; Ogawa K; Ohira H
    Fukushima J Med Sci; 2010 Dec; 56(2):121-7. PubMed ID: 21502712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological therapy of lupus nephritis.
    Fine DM
    JAMA; 2005 Jun; 293(24):3053-60. PubMed ID: 15972568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deterioration of renal function in a patient with lupus.
    Rankin EC; Nield GH; Isenberg DA
    Ann Rheum Dis; 1994 Jan; 53(1):67-71. PubMed ID: 8311561
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome.
    Benseler SM; Bargman JM; Feldman BM; Tyrrell PN; Harvey E; Hebert D; Silverman ED
    Rheumatology (Oxford); 2009 Feb; 48(2):176-82. PubMed ID: 19141574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.
    Melander C; Sallée M; Trolliet P; Candon S; Belenfant X; Daugas E; Rémy P; Zarrouk V; Pillebout E; Jacquot C; Boffa JJ; Karras A; Masse V; Lesavre P; Elie C; Brocheriou I; Knebelmann B; Noël LH; Fakhouri F
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):579-87. PubMed ID: 19261822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.
    Burchardi C; Schlöndorff D
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):314-5. PubMed ID: 16932452
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cyclophosphamide-induced lupus flare in diffuse proliferative lupus nephropathy].
    Heras M; Saiz A; Fernández-Reyes MJ; Sánchez R; Zurita P; Urrego C
    Nefrologia; 2011; 31(2):231-3. PubMed ID: 21461001
    [No Abstract]   [Full Text] [Related]  

  • 18. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
    Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
    Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
    Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
    Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.